The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective translational study investigating molecular predictors of resistance and response to regorafenib (REG) monotherapy in RAS mutant (mt) metastatic colorectal cancer (mCRC): Initial magnetic resonance imaging (MRI) sub-study result.
 
Khurum Hayat Khan
Honoraria - Bayer
 
Mihaela Rata
No Relationships to Disclose
 
Dow-Mu Koh
No Relationships to Disclose
 
Nina Tunariu
No Relationships to Disclose
 
David J. Collins
No Relationships to Disclose
 
Ian Chau
Honoraria - Amgen; Bayer; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck Serono; Sanofi
Research Funding - Merck Serono; Novartis; Roche/Genentech; Sanofi
 
David J. Watkins
No Relationships to Disclose
 
Naureen Starling
No Relationships to Disclose
 
Sheela Rao
Consulting or Advisory Role - Celgene; Lilly; Merck Serono; Roche/Genentech; Sanofi
 
Clare Peckitt
Consulting or Advisory Role - Sanofi
 
Nicos Fotiadis
No Relationships to Disclose
 
Ruwaida Begum
No Relationships to Disclose
 
Claire Saffery
No Relationships to Disclose
 
Janet Thomas
No Relationships to Disclose
 
Marco Gerlinger
No Relationships to Disclose
 
Nicola Valeri
No Relationships to Disclose
 
David Cunningham
Research Funding - Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); MedImmune (Inst); Merck Serono (Inst); Merrimack (Inst); Sanofi (Inst)